Insusense Therapeutics website launches

News

Paul Little, Operating Partner in Lundbeckfonden Emerge, replaces Christian Elling as CEO of Insusense Therapeutics

1. October 2018

Lundbeck Foundation doubles its investment in Aarhus-based Insusense Therapeutics

20. October 2015

About Us

InsuSence Therapeutics is a product-focused biotechnology company based on novel breakthrough science in diabetes biology, which has the potential to quantum leap to important new Type 2 diabetes therapeutics.

News

Paul Little, Operating Partner in Lundbeckfonden Emerge, replaces Christian Elling as CEO of Insusense Therapeutics

1. October 2018

Lundbeck Foundation doubles its investment in Aarhus-based Insusense Therapeutics

20. October 2015

Contact

Insusense ApS
c/o Lundbeckfonden
Scherfigsvej 7
DK-2100 Copenhagen

Privacy Policy